BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 38244662)

  • 1. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
    Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
    Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
    Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
    Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes.
    Jing Z; Li Y; Song J; Zang X
    Int J Biol Macromol; 2023 Dec; 253(Pt 3):126912. PubMed ID: 37722648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microneedles loaded with anti-PD-1-cisplatin nanoparticles for synergistic cancer immuno-chemotherapy.
    Lan X; Zhu W; Huang X; Yu Y; Xiao H; Jin L; Pu JJ; Xie X; She J; Lui VWY; Chen HJ; Su YX
    Nanoscale; 2020 Sep; 12(36):18885-18898. PubMed ID: 32902555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
    Gao M; Wang T; Ji L; Bai S; Tian L; Song H
    Front Immunol; 2020; 11():366. PubMed ID: 32194569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Wu J; Wang W; Gao L; Shao X; Wang X
    Cancer; 2024 Apr; 130(S8):1449-1463. PubMed ID: 38482921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
    Yang Z; Sun JK; Lee MM; Chan MK
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Intelligent Biomimetic Nanoplatform for Holistic Treatment of Metastatic Triple-Negative Breast Cancer
    Cheng Y; Chen Q; Guo Z; Li M; Yang X; Wan G; Chen H; Zhang Q; Wang Y
    ACS Nano; 2020 Nov; 14(11):15161-15181. PubMed ID: 33143424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulator-Mediated Suppressive Tumor Immune Microenvironment Remodeling Nanoplatform for Enhanced Immuno/Chemo/Photothermal Combination Therapy of Triple Negative Breast Cancer.
    Wang A; Yang X; Li R; Shao L; Zhao W; Hu X; Fang K; Chai K; Shi S; Dong C
    ACS Appl Mater Interfaces; 2023 Nov; 15(46):53318-53332. PubMed ID: 37943829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer.
    Lin M; Cai Y; Chen G; Zhong H; Li B; Li T; Xiao Z; Shuai X
    Biomaterials; 2023 May; 296():122067. PubMed ID: 36854221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-Confined Tumor-Docking Reversible Thermogel Potentiates Systemic Antitumor Immune Response During Near-Infrared Photothermal Ablation in Triple-Negative Breast Cancer.
    Revuri V; Rajendrakumar SK; Park MS; Mohapatra A; Uthaman S; Mondal J; Bae WK; Park IK; Lee YK
    Adv Healthc Mater; 2021 Nov; 10(21):e2100907. PubMed ID: 34541833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.